Predictors of competing mortality to invasive breast cancer incidence in the Canadian National Breast Screening study

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Taghipour, Sharareh ^a,b   Banjevic, Dragan ^b   Fernandes, Joanne ^b   Miller, Anthony B ^b   Montgomery, Neil ^b   Jardine, Andrew K S ^b   Harvey, Bart J ^b  

^a RYERSON UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer specific mortality; Competing mortality; Invasive breast cancer; Non cancer mortality; Risk factors

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PHYSICAL EXAMINATION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; BREAST NEOPLASMS; CANADA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84869385274     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-299     Document Type: Article

References (37)

1. Fang F, Valdimarsdottir U, Mucci L, Sparen P, Ye W, Fall K. Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer. Cancer Epidem 2010, 34:644-647.
2. Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do K, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam F. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res 2010, 3:1026-1034.
3. Mell LK, Digram JJ, Salama JK, Cohen EEW, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR. Predictors of Competing Mortality in Advanced Head and Neck Cancer. J Clin Oncol 2010, 28(1):15-20. 10.1200/JCO.2008.20.9288, 19933920.
4. Mell LK, Jeong JH, Nichols MA, Polite BN, Weichselbaum RR, Chmura SJ. Predictors of competing mortality in early breast cancer. Cancer 2010, 116(23):5365-5373. 10.1002/cncr.25370, 20737562.
5. Rosenberg MA. Chapter 3: Competing risks to breast cancer mortality. J Natl Cancer I Monogr 2006, 36:15-19.
6. Vilaprinyo E, Gispert R, Martínez-Alonso M, Carles M, Pla R, Espinàs JA, Rué M. Competing risks to breast cancer mortality in Catalonia. BMC Cancer 2008, 8:331. 10.1186/1471-2407-8-331, 2636833, 19014473.
7. Lambert PC, Holmberg L, Sandin F, Bray F, Linklater KM, Purushotham A, Robinson D, Moller H. Quantifying differences in breast cancer survival between England and Norway. Cancer Epidem 2011, 35:526-533.
8. Daskivich TJ, Chamie K, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 2011, 117(20):4642-4650. 10.1002/cncr.26104, 21480201.
9. Barnes BBE, Steindorf K, Hein R, Flesch-Janys D, Chang-Claude J. Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors. Cancer Epidem 2011, 35:345-352.
10. Taghipour S, Banjevic D, Fernandes J, Miller AB, Montgomery N, Harvey B, Jardine AKS. Incidence of invasive breast cancer in the presence of competing mortality: The Canadian National Breast Screening Study. Breast Cancer Res Treat 2012, 134(2):839-851. 10.1007/s10549-012-2113-6, 22689090.
11. Miller AB, Baines CJ, To T, Wall C. Canadian national breast screening study: 1. Breast cancer detection and death rates among women age 40-49 years. Can Med Assoc J 1992, 147(10):1459-1476.
12. Miller AB, Baines CJ, To T, Wall C. Canadian national breast screening study: 2. Breast cancer detection and death rates among women age 50-59 years. Can Med Assoc J 1992, 147(10):1477-1488.
13. US Preventive Services Task Force Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005, 143:355-361. US Preventive Services Task Force.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94(446):496-509.
15. Pintilie M. Competing Risks: A Practical Perspective 2006, John Wiley & Sons, New York.
16. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data 1980, Wiley, New York, 1.
17. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE, Grodstein F, Stampfer MJ, Colditz GA. Postmenopausal hormone therapy and mortality. N Engl J Med 1997, 336:1769-1775. 10.1056/NEJM199706193362501, 9187066.
18. Bush TL, Cowan LD, Barrett-Connor E, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen Use and All-Cause Mortality Preliminary Results From the Lipid Research Clinics Program Follow-up Study. J Am Med Assoc 1983, 249(7):903-906.
19. Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, van der Schouw YT. Age at menopause, cause-specific mortality and total life expectancy. Epidem 2005, 16(4):556-562.
20. Cutler WB. Hormones and Your Health: The Smart Woman's Guide to Hormonal and Alternative Therapies for Menopause 2009, John Wiley & Sons, New Jersey.
21. Hurt LS, Ronsmans C, Thomas SL. The effect of number of births on women's mortality: Systematic review of the evidence for women who have completed their childbearing. Population Stud 2006, 60(1):55-71.
22. Kuningas M, Altmäe S, Uitterlinden AG, Hofman A, van Duijn CM, Tiemeier H. The relationship between fertility and lifespan in humans. Age 2011, 33:615-622. 10.1007/s11357-010-9202-4, 3220400, 21222045.
23. Grundy E, Kravdal T. Reproductive History and Mortality in Late Middle Age among Norwegian Men and Women. Am J Epidemiol 2008, 167:271-279.
24. Blow AJ, Swiecicki P, Haan P, Osuch JR, Symonds LL, Smith SS, Walsh K, Boivin MJ. The Emotional Journey of Women Experiencing a Breast Abnormality. Qual Health Res 2011, 21(10):1316-1334. 10.1177/1049732311405798, 21511978.
25. Wolbers M, Koller MT, Witteman JCM, Steyerberg EW. Prognostic Models with Competing Risks Methods and Application to Coronary Risk Prediction. Epidemiology 2009, 20(4):555-561. 10.1097/EDE.0b013e3181a39056, 19367167.
26. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics 2005, 6:227-239. 10.1093/biostatistics/kxi005, 15772102.
27. Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 2007, 83:1586-1592. 10.1016/j.athoracsur.2006.11.044, 17462363.
28. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005, 365:434-441.
29. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007, 13:559-565. 10.1158/1078-0432.CCR-06-1210, 17255278.
30. Lim HJ, Zhang X, Dyck R, Osgood N. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes. BMC Med Res Methodol 2010, 10:97. 10.1186/1471-2288-10-97, 2988010, 20964855.
31. Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips KA. Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genet Med 2011, 13(10):853-860. 10.1097/GIM.0b013e31821f3e64, 21637102.
32. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer I 1989, 81:1879-1886.
33. National Cancer Institute Breast Cancer Risk Assessment Tool. http://www.cancer.gov/bcrisktool/ , National Cancer Institute.
34. Afonso N. Women at high risk for breast cancer - what the primary care provider needs to know. J Am Board Fam Med 2009, 22(1):43-50. 10.3122/jabfm.2009.01.070188, 19124632.
35. Pintilie M. Analysing and interpreting competing risk data. Stat Med 2007, 26:1360-1367. 10.1002/sim.2655, 16900575.
36. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007, 26(11):2389-2430. 10.1002/sim.2712, 17031868.
37. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 2010, 48:S96-S105.